Type
|
Public company |
---|---|
Traded as | NASDAQ: IOSP S&P 600 Component |
Industry | Oil and gas |
Headquarters | United States |
Products | Specialty chemicals |
Number of employees
|
1,300 |
Website | www.innospecinc.com |
Innospec Inc., formerly known as Octel Corporation and Associated Octel Company, Ltd., is a global specialty chemical company. It comprises three business units: Fuel Specialties, responsible for the development and supply of additives for fuels and which also includes the company's activities in its Oilfield Chemicals division, Performance Chemicals, which focuses on products for the Personal Care industry and also provides products for the Polymers markets, and Octane Additives, which is the last remaining non-Chinese producer of tetraethyllead (TEL) used in the manufacture of motor gasoline in one remaining country and 100LL avgas throughout the world.The company has recently sparked controversy due to it being the only company which continues to export leaded petrol from the UK to Algeria despite pledging to stop several times and direct links to childhood brain damage and premature death.
Innospec is headquartered in Englewood, Colorado, and has major regional centers in the United Kingdom and Singapore, along with international offices and processing facilities in China, UAE, Cyprus, South Korea, and India.[1]
Production plants are located in multiple countries including UK, France, Germany, Philippines, and the United States.
The company has around 1300 employees located in 20 countries.
Innospec has made the following recent acquisitions and divestments:
Innospec markets detergents, cold flow improvers, lubricity improvers, corrosion inhibitors, antioxidants, cetane improvers, TEL, and a range of other chemicals as fuel additives.
The Oilfield Services division provides products and services for drilling, fracturing & stimulation and production operations to customers in the oil and gas industry
In Personal Care, the company makes a range of high performance surfactants, emollients and silicone formulations.
In 2007 US authorities alerted the UK SFO to Innospec's activities which had come to their attention via a UN committee and a complaint filed with SEC involving their Iraqi agents and former company executives. In a 2010 investigation by The Guardian and Guardian Films, Innospec, while trading as company Octel, was revealed to have been bribing officials in Iraq and Indonesia with millions of dollars in order to continue using TEL as a fuel additive, which causes brain damage in children through elevated lead levels. The company negotiated a global settlement, although this was condemned by Lord Justice Thomas of the UK during sentencing. In October 2014 the convictions of Miltiades Papachristos and Dennis Kerrison for conspiracy to corrupt were upheld against appeals. The company was released from its Monitor supervision and successfully completed its parole period in early 2015.
Period | Date | Adjusted Actuals EPS | GAAP EPS |
---|---|---|---|
Q3 2022 | 2022-10-31 | Future report Set alerts | |
Q2 2022 | 2022-08-02 | 1.58 | 1.58 |
Q1 2022 | 2022-05-03 | 1.53 | 1.53 |
Q4 2021 | 2022-02-15 | 1.30 | 1.30 |
Q3 2021 | 2021-11-02 | 1.15 | 1.15 |
Q2 2021 | 2021-08-03 | 1.30 | 1.30 |
Q1 2021 | 2021-05-04 | 1.06 | 1.06 |
Q4 2020 | 2021-02-16 | 1.27 | 1.27 |
Q3 2020 | 2020-11-03 | 0.00 | 0.00 |
Q2 2020 | 2020-08-04 | -0.18 | -1.62 |
2016-04-05 | Upgrade | KeyBanc | Sector Weight to Overweight | $53.00 |
2016-04-05 | Upgrade | KeyCorp | Sector Weight to Overweight | $53.00 |
2015-10-12 | Downgrade | Monness Crespi & Hardt | Buy to Neutral | |
2015-05-01 | Initiated Coverage | Singular Research | Buy | $60.00 |
2014-02-14 | Boost Price Target | Monness Crespi & Hardt | Buy | $46.00 to $53.00 |
2014-02-14 | Downgrade | CJS Securities | Market Perform | |
2013-11-12 | Downgrade | KeyBanc | Buy to Hold | |
2013-02-14 | Reiterated | Monness Crespi & Hardt | Buy | $40 to $46 |
2007-11-16 | Upgrade | JP Morgan | Neutral to Overweight | |
2007-06-20 | Downgrade | Matrix Research | Buy to Hold | |
2007-04-20 | Downgrade | Matrix Research | Buy to Hold |
2016-04-05 | Upgrade | KeyBanc | Sector Weight to Overweight | $53.00 |
2016-04-05 | Upgrade | KeyCorp | Sector Weight to Overweight | $53.00 |
2015-10-12 | Downgrade | Monness Crespi & Hardt | Buy to Neutral | |
2015-05-01 | Initiated Coverage | Singular Research | Buy | $60.00 |
2014-02-14 | Boost Price Target | Monness Crespi & Hardt | Buy | $46.00 to $53.00 |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In IOSP 177 funds of 2213 total. Show all
Fund name | Ticker shares |
---|---|
BlackRock Inc. | 3.95M |
Vanguard Group, Inc | 2.85M |
BlackRock Fund Advisors | 1.90M |
WASATCH ADVISORS INC | 1.60M |
DIMENSIONAL FUND ADVISORS LP | 1.20M |
ROYCE & ASSOCIATES LLC | 1.05M |
VICTORY CAPITAL MANAGEMENT INC | 0.97M |
STATE STREET CORP | 0.91M |
Champlain Investment Partners, LLC | 0.90M |
ALLIANCEBERNSTEIN L.P. | 0.86M |
BlackRock Institutional Trust Company, N.A. | 0.64M |
HENDERSON GROUP PLC | 0.51M |
GEODE CAPITAL MANAGEMENT, LLC | 0.45M |
NORTHERN TRUST CORP | 0.40M |
Nuveen Asset Management, LLC | 0.33M |